We are live on
!
Find out more
TGI
TRV GP IV Portfolio holdings
AUM
$267M
1-Year Est. Return
965.83%
This Fund
S&P 500
This Quarter
Est. Return
-52.54%
1 Year Est. Return
+965.83%
3 Year Est. Return
+686.22%
5 Year Est. Return
+581.56%
10 Year Est. Return
–
AUM
$45.6M
AUM Growth
–
Cap. Flow
+$68.2M
Cap. Flow
% of AUM
149.48%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dianthus Therapeutics
DNTH
|
+$68.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dianthus Therapeutics
DNTH
$5.84B
| $45.6M | 100% |
+500,513
| New | +$68.2M |
|
Similar funds
OPL
WAM
IP
SIA
CFG
EU
PC
ALC
TRV GP IV's Q4 2018 Portfolio in Review
Q4 2018 is the first quarter with a 13F filing on record for TRV GP IV, which disclosed 1 position worth $45.6M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Dianthus Therapeutics: 500,513 shares worth $45.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- TRV GP IV's largest Q4 2018 buy was Dianthus Therapeutics: 500,513 shares worth $45.6M.
- TRV GP IV's ten largest holdings make up 100% of its $45.6M portfolio in Q4 2018.
- TRV GP IV disclosed 1 position in Q4 2018, its first 13F filing on record.
Based on TRV GP IV's 13F filing for Q4 2018, filed 28 Jan 2019.